A Phase 2 interventional study of Inotuzumab Ozogamicin (CMC-544) in Lymphoma, sponsored by Pfizer. Completed at 42 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-31.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.
5,579 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 81 is above the median of 40 across 4,509 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
inotuzumab ozogamicin
Drug: Inotuzumab Ozogamicin (CMC-544)
Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
Also known as: inotuzumab ozogamicin
Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (less than or equal to \[≤\]1.5 cm in their greatest transverse diameter \[GTD\] for nodes more than \[\>\]1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as \>50% decrease in the sum of the product diameters (SPD) of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by greater than or equal to \[≥\]50% in the SPD or GTD (for single nodules). With exception of splenic and hepatic nodules, involvement of other organs was usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Percentage of Participants With Follicular NHL Achieving CR or PR According to International Response Criteria for NHL
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their greatest transverse diameter for nodes \>1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as \>50% decrease in the SPD of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or greatest transverse diameter (for single nodules). With exception of splenic and hepatic nodules, involvement of other organs was usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Percentage of Participants With Indolent NHL Achieving a CR According to International Response Criteria for NHL
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their greatest transverse diameter for nodes \>1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Percentage of Participants With Follicular NHL Achieving a CR According to International Response Criteria for NHL
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their greatest transverse diameter for nodes \>1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Duration of Response in Participants With Indolent NHL
Duration of response was measured from the first date of response until the first date that the objective progression of disease (PD) or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Probability of Maintaining a Response at 6, 12 and 24 Months in Participants With Indolent NHL
Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: 6, 12 and 24 months
Duration of Response in Participants With Follicular NHL
Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Probability of Maintaining a Response at 6, 12 and 24 Months in Participants With Follicular NHL
Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: 6, 12 and 24 months
Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in Participants With Indolent NHL
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12 and 24 Months in Participants With Indolent NHL
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: 6, 12 and 24 months
Kaplan-Meier Estimate of the PFS in Participants With Follicular NHL
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to progression of disease or death from any cause. Events were defined as death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Kaplan-Meier Estimate of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12 and 24 Months in Participants With Follicular NHL
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to progression of disease or death from any cause. Events were defined as death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
Time frame: 6, 12 and 24 months
Kaplan-Meier Estimate of the Overall Survival (OS) in Participants With Indolent NHL
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
Time frame: Any time up to 2 years after enrollment. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Kaplan-Meier Estimates of the Probability of Survival at 6, 12 and 24 Months in Participants With Indolent NHL
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
Time frame: 6, 12 and 24 months
Kaplan-Meier Estimate of the OS in Participants With Follicular NHL
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
Time frame: Any time up to 2 years after enrollment. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Kaplan-Meier Esitmates of the Probability of Survival at 6, 12 and 24 Months in Participants With Follicular NHL
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
Time frame: 6, 12 and 24 months
Median Induced Change From Baseline of QT Study Specific Correction (QTcS) by Cycle Based on Median Maximum Calicheamicin Concentration (Cmax)
Triplicate 12-lead electrocardiogram (ECG) measurements were performed approximately 2 minutes apart. ECG assessments were pre-specified in the protocol to be time-matched with selected pharmacokinetic (PK) samples in order to conduct a concentration-QTc analysis. A study-specific QT correction factor was estimated using the un-averaged triplicate data and was used to calculate the study-specific corrected QT (QTcS). QTcS interval versus serum concentrations were modeled using a population analysis approach to identify potential effects of total calicheamicin exposure. Results for drug effects were based on the median Cmax for total calicheamicin across all participants: median Cmax was 61.3 ng/mL
Time frame: Cycle 1: pre-dose, 1 hour; Cycle 3 & 4: pre-dose, 1, 3, 48, 168 hours; Cycle 6 (if applicable): pre-dose; end of treatment: during clinic visit
Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)
Includes all TEAEs: any event that emerged after the first dose of the study treatment during the treatment period that was absent before administration of any study treatment, or worsened during the treatment period relative to the pre-treatment state.
Time frame: Protocol reporting period: from informed consent to at least 28 days after the last dose.
Percentage of Participants With QTc Interval Corrected Using Fridericia's Formula (QTcF) by Category (Safety Population)
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Maximum QTcF was categorized as less than or equal to (≤) 450 msec, \>450 msec to ≤480 msec, \>480 msec to ≤500 msec and \>500 msec. Participants are reported only once under the maximum QTcF interval observed at any of the time-points. Maximum increase from baseline was categorized as \<30 msec, ≥30 to \<60 msec (borderline) and ≥60 msec (prolonged) were summarized.
Time frame: Screening; Cycle 1: pre-dose & 1 hour; Cycles 3 and 4: pre-dose, 1, 3, 48, and 168 hours; Cycle 6: pre-dose; end of treatment: 28 to 56 days post-last dose.
| Milestone | Inotuzumab Ozogamicin - NHL Type (Follicular) | Inotuzumab Ozogamicin - NHL Type (Marginal Zone) | Inotuzumab Ozogamicin - NHL Type (Small Lymphocytic) |
|---|---|---|---|
| Started | 72 | 4 | 5 |
| Completed | 49 | 1 | 0 |
| Not completed | 23 | 3 | 5 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 |
| Withdrew: Death | 16 | 2 | 4 |
| Withdrew: Other - unspecified | 1 | 0 | 0 |
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (less than or equal to \[≤\]1.5 cm in their greatest transverse diameter \[GTD\] for nodes more than \[\>\]1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as \>50% decrease in the sum of the product diameters (SPD) of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by greater than or equal to \[≥\]50% in the SPD or GTD (for single nodules). With exception of splenic and hepatic nodules, involvement of other organs was usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions.
| Percentage of Participants | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL | 66.7 (55.32 to 76.76) |
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their greatest transverse diameter for nodes \>1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as \>50% decrease in the SPD of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or greatest transverse diameter (for single nodules). With exception of splenic and hepatic nodules, involvement of other organs was usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions.
| Percentage of Participants | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| Percentage of Participants With Follicular NHL Achieving CR or PR According to International Response Criteria for NHL | 70.8 (58.93 to 80.95) |
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their greatest transverse diameter for nodes \>1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy.
| Percentage of Participants | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| Percentage of Participants With Indolent NHL Achieving a CR According to International Response Criteria for NHL | 30.9 (21.07 to 42.11) |
CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their greatest transverse diameter for nodes \>1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy.
| Percentage of Participants | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| Percentage of Participants With Follicular NHL Achieving a CR According to International Response Criteria for NHL | 34.7 (23.88 to 46.86) |
Duration of response was measured from the first date of response until the first date that the objective progression of disease (PD) or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Months | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| Duration of Response in Participants With Indolent NHL | 24.8 (10.9 to NA) |
Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Probability | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| 6 Month Probability of Maintaining a Response | 0.82 (0.68 to 0.90) |
| 12 Month Probability of Maintaining a Response | 0.65 (0.50 to 0.77) |
| 24 Month Probability of Maintaining a Response | 0.53 (0.38 to 0.66) |
Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Months | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| Duration of Response in Participants With Follicular NHL | 24.8 (12.9 to NA) |
Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Probability | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| 6 Month Probability of Maintaining a Response | 0.85 (0.71 to 0.92) |
| 12 Month Probability of Maintaining a Response | 0.67 (0.51 to 0.79) |
| 24 Month Probability of Maintaining a Response | 0.57 (0.40 to 0.70) |
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Months | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in Participants With Indolent NHL | 12.7 (8.9 to 26.9) |
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Percent Probability | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| 6 Months | 65.1 (53.3 to 74.6) |
| 12 Months | 52.0 (40.0 to 62.7) |
| 24 Months | 41.3 (29.8 to 52.5) |
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to progression of disease or death from any cause. Events were defined as death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Months | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| Kaplan-Meier Estimate of the PFS in Participants With Follicular NHL | 14.7 (11.0 to NA) |
Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to progression of disease or death from any cause. Events were defined as death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by ≥50% of previously involved sites from nadir, 2) New lesion(s) \>1.5 cm (any axis); ≥50% increase in SPD of \>1 node; or ≥50% increase in longest diameter of previously identified node \>1 cm in short axis, 3) \>50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow.
| Percenr probability | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| 6 Months | 69.3 (56.8 to 78.8) |
| 12 Months | 56.3 (43.4 to 67.3) |
| 24 Months | 46.1 (33.5 to 57.8) |
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
| Months | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| Kaplan-Meier Estimate of the Overall Survival (OS) in Participants With Indolent NHL | NA (26.6 to NA) |
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
| Probability | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| 6 Months | 0.89 (0.79 to 0.94) |
| 12 Months | 0.80 (0.69 to 0.87) |
| 24 Months | 0.73 (0.61 to 0.81) |
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
| Months | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| Kaplan-Meier Estimate of the OS in Participants With Follicular NHL | NA (NA to NA) |
Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact.
| Probability | Inotuzumab Ozogamicin - NHL Type (Follicular) |
|---|---|
| 6 Months | 0.91 (0.82 to 0.96) |
| 12 Months | 0.83 (0.72 to 0.90) |
| 24 Months | 0.78 (0.67 to 0.86) |
Triplicate 12-lead electrocardiogram (ECG) measurements were performed approximately 2 minutes apart. ECG assessments were pre-specified in the protocol to be time-matched with selected pharmacokinetic (PK) samples in order to conduct a concentration-QTc analysis. A study-specific QT correction factor was estimated using the un-averaged triplicate data and was used to calculate the study-specific corrected QT (QTcS). QTcS interval versus serum concentrations were modeled using a population analysis approach to identify potential effects of total calicheamicin exposure. Results for drug effects were based on the median Cmax for total calicheamicin across all participants: median Cmax was 61.3 ng/mL
| Milliseconds (msec) | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| Cycle 1 | 3.51 (1.85 to 5.40) |
| Cycle 2 | 5.00 (3.19 to 6.80) |
| Cycle 3 | 6.41 (4.01 to 8.64) |
| Cycle 4 | 7.83 (4.83 to 10.8) |
Includes all TEAEs: any event that emerged after the first dose of the study treatment during the treatment period that was absent before administration of any study treatment, or worsened during the treatment period relative to the pre-treatment state.
| Percentage of Participants | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| % participants with a TEAE | 96.3 |
| % participants with serious TEAE | 18.5 |
| % participants with Grade 3 or higher TEAE | 77.8 |
| % participants for study drug discontinuation | 58.0 |
| % participants with dose reduction due to TEAE | 33.3 |
| % participants for study drug stopped temporarily | 48.1 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Maximum QTcF was categorized as less than or equal to (≤) 450 msec, \>450 msec to ≤480 msec, \>480 msec to ≤500 msec and \>500 msec. Participants are reported only once under the maximum QTcF interval observed at any of the time-points. Maximum increase from baseline was categorized as \<30 msec, ≥30 to \<60 msec (borderline) and ≥60 msec (prolonged) were summarized.
| Percentage of Participants | Inotuzumab Ozogamicin - Total (All NHL Types) |
|---|---|
| % participants with QTcF ≤450 ([msec) | 83.1 |
| % participants with QTcF >450 to ≤480 (msec) | 14.3 |
| % participants with QTcF >480 to ≤500 (msec) | 2.6 |
| % participants with QTcF >500 (msec) | 0 |
| % participants with any baseline increase | 98.7 |
| % participants baseline increase <30 (msec) | 79.2 |
| % participants baseline increase ≥30 to <60 (msec) | 18.2 |
| % participants baseline increase ≥60 (msec) | 1.3 |
Collected over Collected from time of informed consent up to a minimum of 28 days after last dose of study drug. Adverse event (AE) summaries below are inclusive of AEs from first dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inotuzumab Ozogamicin - NHL Type (Follicular) | — | 12/72 (16.7%) | 69/72 (95.8%) |
| Inotuzumab Ozogamicin - NHL Type (Marginal Zone) | — | 2/4 (50%) | 4/4 (100%) |
| Inotuzumab Ozogamicin - NHL Type (Small Lymphocytic) | — | 1/5 (20%) | 5/5 (100%) |
| Event | Inotuzumab Ozogamicin - NHL Type (Follicular) | Inotuzumab Ozogamicin - NHL Type (Marginal Zone) | Inotuzumab Ozogamicin - NHL Type (Small Lymphocytic) |
|---|---|---|---|
| Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/72 | 1/4 | 0/5 |
| NauseaGastrointestinal disorders | 0/72 | 1/4 | 0/5 |
| FatigueGeneral disorders | 0/72 | 1/4 | 0/5 |
| PneumoniaInfections and infestations | 2/72 | 1/4 | 1/5 |
| Decreased appetiteMetabolism and nutrition disorders | 0/72 | 1/4 | 0/5 |
| PyrexiaGeneral disorders | 2/72 | 0/4 | 1/5 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/72 | 0/4 | 1/5 |
| SepsisInfections and infestations | 2/72 | 0/4 | 0/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/72 | 0/4 | 0/5 |
| Abdominal distensionGastrointestinal disorders | 1/72 | 0/4 | 0/5 |
| Event | Inotuzumab Ozogamicin - NHL Type (Follicular) | Inotuzumab Ozogamicin - NHL Type (Marginal Zone) | Inotuzumab Ozogamicin - NHL Type (Small Lymphocytic) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 40/72 | 1/4 | 4/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 55/72 | 3/4 | 2/5 |
| FatigueGeneral disorders | 34/72 | 3/4 | 2/5 |
| LeukopeniaBlood and lymphatic system disorders | 26/72 | 2/4 | 1/5 |
| LymphopeniaBlood and lymphatic system disorders | 25/72 | 2/4 | 1/5 |
| NauseaGastrointestinal disorders | 35/72 | 2/4 | 1/5 |
| Aspartate aminotransferase increasedInvestigations | 32/72 | 2/4 | 1/5 |
| Decreased appetiteMetabolism and nutrition disorders | 20/72 | 2/4 | 1/5 |
| Protein urine presentInvestigations | 0/72 | 0/4 | 2/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/72 | 1/4 | 2/5 |
| Age, Continuous(Years) | Inotuzumab Ozogamicin - NHL Type (Follicular) | Inotuzumab Ozogamicin - NHL Type (Marginal Zone) | Inotuzumab Ozogamicin - NHL Type (Small Lymphocytic) | Total |
|---|---|---|---|---|
| Mean | 60.5 ± 10.2 | 70.8 ± 13.5 | 65.2 ± 10.0 | 61.3 ± 10.5 |
| Sex: Female, Male(Participants) | Inotuzumab Ozogamicin - NHL Type (Follicular) | Inotuzumab Ozogamicin - NHL Type (Marginal Zone) | Inotuzumab Ozogamicin - NHL Type (Small Lymphocytic) | Total |
|---|---|---|---|---|
| Female | 35 | 2 | 0 | 37 |
| Male | 37 | 2 | 5 | 44 |
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer